Sulindac inhibits pancreatic carcinogenesis in LSL-Kras(G12D)-LSL-Trp53(R172H)-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10)

Sulindac has been identified as a competitive inhibitor of aldo-keto reductase 1B10 (AKR1B10), an enzyme that plays a key role in carcinogenesis. AKR1B10 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and exhibits lipid substrate specificity, especially for farnesyl and geranylgeranyl....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Li, Haonan, Yang, Allison L., Chung, Yeon Tae, Zhang, Wanying, Liao, Jie, Yang, Guang-Yu
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2013
Teme:
Original Manuscript
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3765049/
https://ncbi.nlm.nih.gov/pubmed/23689354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgt170
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items